Home Patent Forecast® Sectors Log In   Sign Up   Support   Contact  
Why Patent Forecast® What's Included Patent Forecast® Sectors Free Trial Pricing News Feed Subscribe Menu
Enjoy your FREE PREVIEW which shows only 2018 data and 25 documents. For full access, subscribe at any time.         Subscribe


Read More News and Insights

Epidiolex Gets FDA’s Approval to Treat Rare Genetic Disease

Cannabis Patent Forecast®

August 6, 2020

GW Pharmaceuticals received some good news from the FDA a few days ago as they approved the use of Epidiolex “for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.” Previously, Epidiolex had the FDA’s approval to treat seizures from two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS).

Currently, GW Pharmaceuticals is the leading assignee of patents related to cannabis, especially for the use of cannabinoids in the treatment of epilepsy and other neurological disorders. GW’s portfolio nearly spans the entire Magic Number Cannabis Patent Forecast®. 

Explore GW Pharmaceuticals’ extensive cannabis patent portfolio at an advantage using Magic Number’s Cannabis Patent Forecast®.  

EPIDIOLEX® (cannabidiol), the First FDA Approved CBD Drug

Article Source Link


Read more like this in News This Week!   or   Share this link with your connections!